British health officials selected GlaxoSmithKline's Rotarix vaccine for the country's first routine rotavirus immunization program.
A GlaxoSmithKline malaria vaccine posted surprisingly lackluster results in a Phase III trial, putting a damper on solid results from previous studies. The vaccine against the mosquito-borne illness proved only 30% effective when given to African children in a clinical trial.
Continuing a streak of donations to the field of vaccine research and biotech in general, the Bill & Melinda Gates Foundation granted $100,000 to an AgResearch scientist for research into a new tuberculosis vaccination method.
Good news out of Canada in the search for an HIV vaccine: Scientists announced a vaccine candidate showed no adverse effects and significantly boosted immunity in human trials.
Health officials have clashed over the effectiveness of a pricey malaria program intended to provide cheap drugs for poor patients.
A recent study shows close, repeated contact with a person with mumps can overwhelm the mumps vaccine.
Oral vaccines prove an alluring alternative to painful shots, and scientists at Royal Holloway, University of London, are pioneering a new method of oral vaccination using probiotic spores--"good bacteria." The method could help boost immunity to tuberculosis and influenza, as well as prevent C. difficile.
A Centers for Disease Control and Prevention panel recommended the use of GlaxoSmithKline's MenHibrix vaccine for bacterial meningitis for use in babies at increased risk of infection.
Genocea Biosciences has raised $30 million in a Series C financing round to advance its T-cell vaccines for infectious diseases. With the close of this financing round, the clinical-stage company has landed a total of $76 million in equity financing to date.
GlaxoSmithKline ($GSK) will work with nonprofit biotech Aeras to test a tuberculosis vaccine in Africa and India, making headway in developing new ways to prevent the disease.